Cross-sectional and prospective relationships of apoA-I and apoB100 with subclinical atherosclerosis

apoA-I 和 apoB100 与亚临床动脉粥样硬化的横断面和前瞻性关系

• 批准号: 17K15826
• 负责人: ZAID MARYAM
• 金额: $ 1.75万
• 依托单位: Shiga University of Medical Science
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2017
• 资助国家: 日本
• 起止时间: 2017-04-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17K15826/
• 关键词: apoA1; apoB; atherosclerosis; apoA-I; apoB100; epidemiology

We have fully completed our study on serum measurements of apoA1 and apoB and subclinical atherosclerosis. We have found that both apoA1 and apoB have significant relationships with carotid intima-media thickness, a marker of subclinical atherosclerosis. These relationships, however, are dependent on their lipid counterparts: HDL-P and LDL-P.In our longitudinal analyses, we could not find any significant relationship between the changes in apoprotein levels and evidence of clinical improvements in coronary subclinical atherosclerosis. Neither apoA1, nor apoB was significantly related to changes in total agatston score.We are currently in the manuscript write-up stage of this study. We hope to soon submit to International SCI journals, such as Atherosclerosis, ATVB and Heart.

我们已经完全完成了 apoA1 和 apoB 血清检测与亚临床动脉粥样硬化的研究。我们发现apoA1和apoB与颈动脉内膜中层厚度（亚临床动脉粥样硬化的标志物）有显着关系。然而，这些关系取决于它们的脂质对应物：HDL-P 和 LDL-P。在我们的纵向分析中，我们无法发现脱辅基蛋白水平的变化与冠状动脉亚临床动脉粥样硬化临床改善的证据之间存在任何显着关系。 apoA1 和 apoB 都与总分的变化没有显着相关。我们目前正处于这项研究的手稿撰写阶段。我们希望尽快投稿到国际SCI期刊，如Atherosclerosis、ATVB、Heart等。